Literature DB >> 3893438

Sparteine increases insulin release by decreasing the K+ permeability of the B-cell membrane.

G Paolisso, M Nenquin, W Schmeer, F Mathot, H P Meissner, J C Henquin.   

Abstract

The effects of sparteine on the pancreatic B-cell function have been studied with mouse islets. In the presence of a non-stimulatory concentration of glucose (3 mM), sparteine (0.2-1 mM) decreased the rate of 86Rb+ efflux from islet cells, depolarized the B-cell membrane, induced a glucose-like electrical activity and stimulated insulin release. This increase in release was observed over a large range of glucose concentrations (3-20 mM), and was most marked in the presence of 10 mM glucose. At this concentration of glucose, the effect of sparteine was already detected with 0.02 mM and was maximal with 0.5 mM. Higher concentrations of sparteine only had a transient effect on insulin release. In the presence of 10 mM glucose, 0.2 mM sparteine decreased 86Rb+ efflux and increased 45Ca2+ efflux from islet cells. The effect on 86Rb+ efflux was only transient in the presence of extracellular calcium, whereas the effect on 45Ca2+ efflux required the presence of extracellular calcium. The electrical activity induced by glucose in B-cells was augmented by sparteine which, at a concentration of 0.5 mM, produced a persistent depolarization with continuous spike activity. The potentiation of insulin release by sparteine was not reversible, but was inhibited by adrenaline and completely blocked by omission of extracellular calcium. Sparteine reversed the increase in 86Rb+ efflux and the decrease in insulin release caused by diazoxide. These results show that sparteine increases insulin release by reducing the K+-permeability of the B-cell membrane.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3893438     DOI: 10.1016/0006-2952(85)90794-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide.

Authors:  M G Garrino; W Schmeer; M Nenquin; H P Meissner; J C Henquin
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

2.  Amantadine and sparteine inhibit ATP-regulated K-currents in the insulin-secreting beta-cell line, HIT-T15.

Authors:  F M Ashcroft; A J Kerr; J S Gibson; B A Williams
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

3.  Effect of sparteine sulphate upon basal and nutrient-induced insulin and glucagon secretion in normal man.

Authors:  S Sgambato; G Paolisso; N Passariello; M Varricchio; F D'Onofrio
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Plasma glucose lowering effect of sparteine sulphate infusion in non-insulin dependent (type 2) diabetic subjects.

Authors:  G Paolisso; S Sgambato; N Passariello; G Pizza; R Torella; P Tesauro; M Varricchio; F D'Onofrio
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Lupanine Improves Glucose Homeostasis by Influencing KATP Channels and Insulin Gene Expression.

Authors:  Mats Wiedemann; Carmen M Gurrola-Díaz; Belinda Vargas-Guerrero; Michael Wink; Pedro M García-López; Martina Düfer
Journal:  Molecules       Date:  2015-10-20       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.